Market Place
Sourcing Support
Insmed Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)
07 Nov 2024 //
PR NEWSWIRE
Insmed Reports Q3 2024 Results and Business Update
31 Oct 2024 //
PR NEWSWIRE
Insmed Ranks No. 1 on Science`s 2024 Top Biopharma Employers List
24 Oct 2024 //
PR NEWSWIRE
Insmed To Host Q3 2024 Financial Results Conference Call On Oct 31
17 Oct 2024 //
PR NEWSWIRE
New Subgroup Analyses From Landmark Phase 3 ASPEN of Brensocatib
08 Oct 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 Sep 2024 //
PR NEWSWIRE
Insmed Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02 Aug 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Jul 2024 //
PR NEWSWIRE
New Positive Data From Brensocatib Study To Be Presented At Conference
03 Jul 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 Jun 2024 //
PR NEWSWIRE
Insmed to Host Commercial Webinar on June 4, 2024
30 May 2024 //
PR NEWSWIRE
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
30 May 2024 //
PR NEWSWIRE
Insmed shares double as lung drug data convince Wall Street
29 May 2024 //
BIOPHRAMADIVE
Insmed: Positive Topline ASPEN Data For Brensocatib In Bronchiectasis
28 May 2024 //
PR NEWSWIRE
Insmed Announces Proposed $500 Million Public Offering of Common Stock
28 May 2024 //
PR NEWSWIRE
Insmed Presents ARIKAYCE NTM PRO, Microbiology Data At ATS
20 May 2024 //
PR NEWSWIRE
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
09 May 2024 //
PR NEWSWIRE
Insmed to Host Q1 2024 Results Call on May 9
25 Apr 2024 //
PRESS RELEASE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Apr 2024 //
PR NEWSWIRE
Insmed to Present Data from Across its Respiratory Portfolio at the Conference
27 Mar 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Mar 2024 //
PR NEWSWIRE
Insmed encourages people to `Speak Up` in new marketing effort
01 Mar 2024 //
ENDPTS
Insmed To Present at Three March Conferences
29 Feb 2024 //
PRESS RELEASE
Actress Jane Seymour and Insmed Raise Awareness of "Unseenism"
28 Feb 2024 //
PRESS RELEASE
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Result
22 Feb 2024 //
PRESS RELEASE
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference
08 Feb 2024 //
PRESS RELEASE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02 Feb 2024 //
PR NEWSWIRE
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
05 Jan 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04 Jan 2024 //
PRESS RELEASE
Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05 Dec 2023 //
PR NEWSWIRE
Insmed To Present at the Nasdaq 49th Investor Conference
29 Nov 2023 //
PRESS RELEASE
Insmed To Present at Two November Conferences
08 Nov 2023 //
PRESS RELEASE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Nov 2023 //
PR NEWSWIRE
Insmed Holds Second Annual Global Day of Good to Benefit Communities
02 Nov 2023 //
PRESS RELEASE
Insmed earnings beat by $0.02, revenue fell short of estimates
26 Oct 2023 //
PRESS RELEASE
Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
26 Oct 2023 //
PR NEWSWIRE
Insmed Ranks No. 1 on Science`s 2023 Top Biopharma Employers List
26 Oct 2023 //
PR NEWSWIRE
Insmed and Google Cloud Collaborate to Transform the Lives of Patients
24 Oct 2023 //
PR NEWSWIRE
Insmed to Host Third-Quarter 2023 Financial Results Conference
12 Oct 2023 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 Oct 2023 //
PRESS RELEASE
Insmed To Present at Chardan`s 7th Annual Genetic Medicines Conference
26 Sep 2023 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08 Sep 2023 //
PR NEWSWIRE
Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 Sep 2023 //
PR NEWSWIRE
Insmed to Host Second-Quarter 2023 Financial Results Conference
20 Jul 2023 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 Jul 2023 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 Jun 2023 //
PR NEWSWIRE
Insmed Presents Range of New Study Findings at International Conference
22 May 2023 //
PR NEWSWIRE
Insmed to Host Investor and Analyst Event on May 8, 2023
24 Apr 2023 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06 Apr 2023 //
PR NEWSWIRE
Insmed Completes Enrollment of Patients in Phase 3 ASPEN Study of Brensocatib
31 Mar 2023 //
PR NEWSWIRE
Insmed to Present Data in Serious and Rare Lung Diseases
24 Mar 2023 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Mar 2023 //
PR NEWSWIRE
Insmed To Present at Two March Conferences
01 Mar 2023 //
PR NEWSWIRE
Insmed Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
PR NEWSWIRE
Insmed To Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
PR NEWSWIRE
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
20 Jan 2023 //
PR NEWSWIRE
Insmed Provides Business Updates and Near-Term Strategic Outlook at J.P. Morgan
06 Jan 2023 //
PR NEWSWIRE
Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
PR NEWSWIRE
